menu
    • menu

    Company profile for H. Lundbeck AS

    NEW Drugs in Dev: 49
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Guizhou Utide Biotechnology Co., Ltd. - Specialized GMP manufacturing for next-generation GLP-1 peptide APIs.

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    H. Lundbeck ASFlag
    Country
    Country
    --
    Address
    Address
    --
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    --
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    Food Ingredients China

    Not Confirmed

    envelop Contact Supplier

    Food Ingredients China

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Lundbeck advances Parkinson's research with new Phase 1b data
    Lundbeck advances Parkinson's research with new Phase 1b data

    16 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/lundbeck-advances-parkinsons-research-with-new-phase-1b-data-at-adpd-2026-302714458.html

    PR NEWSWIRE
    16 Mar 2026
    Share Share
    Lundbeck Appoints Chief AI Officer
    Lundbeck Appoints Chief AI Officer

    10 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/lundbeck-appoints-chief-ai-officer-302709211.html

    PR NEWSWIRE
    10 Mar 2026
    Share Share
    Lundbeck Reports Positive Ph2B Results For Bocunebart in Migraine
    Lundbeck Reports Positive Ph2B Results For Bocunebart in Migraine

    12 Feb 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-02-12/lundbeck-announces-positive-phase-iib-top-line-results-with-bocunebart-lu-ag09222-anti-pacap-mab-in-migraine-prevention

    PHARMIWEB
    12 Feb 2026
    Share Share
    Lundbeck Presents Vyepti Data on Severe Migraine at HCOP
    Lundbeck Presents Vyepti Data on Severe Migraine at HCOP

    30 Jan 2026

    // PR NEWSWIRE BIO

    https://www.prnewswire.com/news-releases/lundbeck-presents-new-real-world-data-highlighting-meaningful-improvements-in-patients-severely-impacted-by-migraine-initiating-vyepti-eptinezumab-at-hcop-annual-conference-302675109.html

    PR NEWSWIRE BIO
    30 Jan 2026
    Share Share
    After Avadel Setback, Lundbeck Signals Future M&A Rigor
    After Avadel Setback, Lundbeck Signals Future M&A Rigor

    22 Jan 2026

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/lundbeck-not-willing-compromise-ma-strategy-after-missed-avadel-attempt

    FIERCE PHARMA
    22 Jan 2026
    Share Share
    Lundbeck Reveals Bexicaserin's Positive Long-Term Phase 2 Data
    Lundbeck Reveals Bexicaserin's Positive Long-Term Phase 2 Data

    06 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/lundbeck-announces-positive-phase-2-long-term-data-for-bexicaserin-in-rare-childhood-onset-epilepsies-at-american-epilepsy-society-aes-annual-meeting-302634643.html

    PR NEWSWIRE
    06 Dec 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search